Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a global leader in cloud-based software solutions specifically tailored for the life sciences industry. Headquartered in the San Francisco Bay Area, Veeva Systems provides innovative technology that helps pharmaceutical and biotech companies streamline their operations, ensure compliance, and bring products to market faster. Veeva's product offerings address key operational and regulatory needs, ranging from customer relationship management (CRM) to content management and data analytics.
Two of the company's flagship products include Veeva CRM and Veeva Vault. Veeva CRM is designed for companies with a salesforce, providing tools to manage customer interactions more efficiently. Meanwhile, Veeva Vault is a versatile content management platform that supports various functions such as clinical trials, regulatory submissions, and quality management within life sciences companies.
Veeva serves a diverse customer base, ranging from emerging biotechs to some of the world's largest pharmaceutical companies. Its commitment to product excellence, customer success, and continuous innovation is evident as Veeva frequently updates its offerings to meet the evolving needs of the industry. Recently, Veeva announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications to streamline clinical execution and improve regulatory management in its animal health business unit.
Another notable achievement for Veeva was the launch of the Veeva AI Partner Program, designed to help partners integrate Generative AI solutions seamlessly with Veeva Vault applications. This initiative highlights Veeva's ongoing efforts to leverage advanced technologies to enhance its product ecosystem. Furthermore, the introduction of Veeva Vault CRM Campaign Manager aims to simplify and speed up non-personal promotion to healthcare professionals, ensuring consistent and compliant marketing efforts.
Financially, Veeva Systems has shown strong performance with its fiscal year 2024 results reflecting robust growth. The company continues to invest in its innovation engine and strategic partnerships, setting the stage for sustained, profitable growth. Veeva's recent financial outlook for fiscal year 2025 and first quarter results for 2024 further underline its market leadership and operational excellence.
For more information about Veeva Systems, its products, and latest updates, visit www.veeva.com.
Veeva Systems (NYSE: VEEV) has launched a new cloud-based digital Hazard Analysis and Critical Control Point (HACCP) solution as part of its QualityOne Suite. The solution aims to help food and beverage manufacturers streamline food safety processes and improve risk management. Features include global visibility, standardization of HACCP plans, integrated flow diagrams, automatic change notifications, and task reminders. Nestlé, as an early adopter, will implement the solution across its 2,000+ brands in 188 countries to enhance proactive quality management and food safety operations.
Veeva Systems (NYSE: VEEV) has scheduled its fiscal 2025 third quarter financial results announcement for December 5, 2024, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results for the quarter ended October 31, 2024. Prepared remarks will be posted to the investor relations website at approximately 1:05 p.m. PT, and a webcast replay will be available following the live event.
Boehringer Ingelheim, a top 20 global biopharma company, has committed to implementing Veeva Vault CRM (NYSE: VEEV) as its commercial foundation. The company aims to launch up to 25 new treatments by 2030 and plans to expand on its existing Veeva Commercial Cloud solutions, One Medicine, and Amplify platforms. This decision builds upon their long-standing partnership where Veeva has served as their global CRM standard. The implementation is expected to help transform commercial operations, accelerate launch processes, and enable personalized customer engagement.
Veeva Systems' latest Pulse Field Trends Report reveals critical insights about healthcare professional (HCP) engagement in the biopharma industry. The report highlights that while in-person meetings with HCPs have declined by 7% compared to last year, synchronized engagement between sales and marketing can significantly improve outcomes. Currently, 65% of HCP engagements remain unsynchronized.
The data shows that coordinated approaches yield better results: rep meetings followed by digital exposure within 10 days are 30% more likely to result in prescriptions, digital ads after speaker programs increase prescription likelihood by 25%, and HCP website visits following rep meetings boost prescription probability by 60%.
Walgreens (Nasdaq: WBA) and Veeva Systems (NYSE: VEEV) have announced a long-term strategic partnership aimed at improving patient outcomes in the healthcare sector. The collaboration will enhance Veeva Data Cloud products while granting Walgreens access to Veeva's Data Cloud and Clinical Platform.
As a major retail and specialty pharmacy provider, Walgreens will contribute to expanding the breadth of data in Veeva Data Cloud, enabling life sciences companies to better understand market trends and improve patient care. This partnership leverages Walgreens' position as a neighborhood health destination and Veeva's expertise in life sciences software and data services.
Veeva Systems (NYSE: VEEV) has announced its upcoming virtual Investor Day scheduled for Thursday, November 7, 2024. The event will run from 1:30 p.m. to 3:30 p.m. PT (4:30 p.m. to 6:30 p.m. ET). Interested parties can attend the event by registering online through Veeva's investor relations website or via a direct link provided.
The company will broadcast the presentations live on its investor relations website, ir.veeva.com. For those unable to attend the live event, an archived webcast will be made available on the same platform after the event concludes.
This virtual Investor Day provides an opportunity for stakeholders to gain insights into Veeva Systems' performance, strategies, and future outlook directly from the company's leadership team.
Veeva Systems (NYSE: VEEV) announced that 18 of the top 20 medtech companies are using Veeva Development Cloud and Veeva Commercial Cloud applications to streamline processes across the total medtech product lifecycle. Over 125 customers are leveraging Veeva MedTech's expertise and technology from ideation to commercialization.
Veeva MedTech offers end-to-end product lifecycle management with Vault Clinical, Vault RIM, Vault Quality, and Vault Commercial applications. These solutions provide real-time insights, automate processes, and maintain inspection readiness, reducing manual work and improving cross-team collaboration.
The upcoming Veeva MedTech EU Summit in Amsterdam (Nov. 5-7) will feature industry leaders sharing insights and best practices.
Veeva Systems (NYSE: VEEV) has announced an expansion of Veeva Vault QMS, adding new capabilities for managing medtech field actions and product recalls. These features aim to improve oversight, timeliness, and accuracy throughout the field action process, from issue identification to closure.
The new capabilities are fully integrated into Vault QMS, connecting seamlessly with related quality processes such as complaint handling, quality risk management, CAPA, and change control. This integration reduces manual transcription needs and enhances efficiency.
Matt Roberts, senior director of quality systems at Teleflex, praised the collaboration with Veeva MedTech, stating that the new field actions capabilities will help streamline processes and better serve customers. Vishaka Rajaram, senior director of quality strategy at Veeva MedTech, emphasized the complex nature of field actions management and how Veeva Vault QMS addresses industry needs.
Veeva Systems (NYSE: VEEV) has announced a major release of Veeva Site Connect, enhancing clinical trial execution for sites and sponsors. The update includes new capabilities and a streamlined site-centric experience to simplify sponsor-site collaboration. Key features include:
1. Expanded functionality beyond document exchange and safety distribution
2. Optimized site user interface standardized across all trials
3. Open accessibility for all sites globally
4. Fixed-price implementation with 2-4 month setup
Seven of the top 20 biopharmas have already adopted Veeva Site Connect, aiming to reduce time and effort in site start-up, study conduct, and closeout. The platform is part of Veeva Clinical Platform, supporting patients, sites, and sponsors in streamlining clinical trials.
Veeva Systems (NYSE: VEEV) has announced its participation in the upcoming Citi 2024 Global TMT Conference in New York. Paul Shawah, EVP Strategy at Veeva, is scheduled to present on Wednesday, September 4, 2024, at 3:00 p.m. Eastern Time.
The presentation will be webcast live and archived for later viewing. Interested parties can access the webcast through Veeva's investor relations website at https://ir.veeva.com. This event provides an opportunity for investors and analysts to gain insights into Veeva's strategies and market position in the technology, media, and telecommunications sectors.
FAQ
What is the current stock price of Veeva Sys (VEEV)?
What is the market cap of Veeva Sys (VEEV)?
What does Veeva Systems Inc. do?
Where is Veeva Systems Inc. headquartered?
What are Veeva's main products?
Who are Veeva Systems' customers?
What recent partnerships has Veeva announced?
What is the Veeva AI Partner Program?
How has Veeva performed financially recently?
What is Veeva Vault CRM Campaign Manager?
What industry does Veeva Systems primarily serve?
How does Veeva contribute to the life sciences industry?
